OncoMatch/Clinical Trials/NCT05557877
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
Is NCT05557877 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Low-Dose Aspirin for breast carcinoma.
Treatment: Low-Dose Aspirin — This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Demographics
Prior therapy
Cannot have received: systemic therapy for any other cancer
Received systemic treatment for any other cancer at any time
Cannot have received: systemic therapy for any prior or current malignancy
Any prior or current malignancy requiring prior or current systemic therapy
Lab requirements
Blood counts
Hemoglobin >= 9.0 g/dL (obtained <= 30 days prior to registration); Platelet count >= 100,000/mm^3 (obtained <= 30 days prior to registration)
Kidney function
Serum creatinine <= 2.0 mg/dl (obtained <= days prior to registration)
Hemoglobin >= 9.0 g/dL (obtained <= 30 days prior to registration); Platelet count >= 100,000/mm^3 (obtained <= 30 days prior to registration); Serum creatinine <= 2.0 mg/dl (obtained <= days prior to registration)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona · Scottsdale, Arizona
- Mayo Clinic in Florida · Jacksonville, Florida
- Indiana University Simon Comprehensive Cancer Center · Indianapolis, Indiana
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05557877 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy for any other cancer, systemic therapy for any prior or current malignancy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 45 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages